Impact of photobiomodulation for oral mucositis on body weight and BMI of patients with head and neck cancer

Melo, Amanda de Sousa; Andrade, Camila Lima; Dantas, Juliana Borges de Lima; Medrado, Alena Ribeiro Alves Peixoto; Martins, Gabriela Botelho; Lima, Hayana Ramos; Carrera, Manoela

doi:10.1007/s00520-022-06899-6

Cited by 7 publications

(7 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All patients showed signi cant differences in weight and BMI throughout the study period, but patients in the PBM group showed less weight loss (p < 0.01) and lower BMI loss (p < 0.01. Although, in this study, PBM did not prevent the onset of oral mucositis, it decreased its severity (p < 0.01) [25].…”

Section: Discussioncontrasting

confidence: 75%

Use of Photobiomodulation in Patients With Head and Neck Cancer Treated in an Oncology Service

Moura

Cruz

Santos

et al. 2022

Preprint

View full text Add to dashboard Cite

Purpose: The purpose of this study was to evaluate the use of prophylactic photobiomodulation and its relationship with weight loss and the development of oral mucositis in patients with head and neck cancer treated with chemoradiotherapy in an oncology service.Methods: This is a retrospective cohort study that included patients who received radiation therapy concomitantly with systemic therapy for treatment of head and neck cancer. Patients were divided into two groups: 1) who received photobiomodulation (PMB) treatment and 2) who did not receive PMB. Results: Thirty patients were included in the study, 15 in each group, with a mean age of 62 years in the PBM group and 63.2 years in the control group. Most patients were male, with locally advanced disease (clinical stage III or IV), and received definitive intent treatment with concomitant radiotherapy to high-dose cisplatin (100 mg/m² every 3 weeks). In this analysis, the use of PBM shows a protective effect against the development of grade 3 or 4 oral mucositis [Odds Ratio 0.22 (0.04-1.11)], and was associated with a risk reduction of weight loss higher than 5% of 8% (relative risk, 0.92; 95% CI, 0.62 – 1.36). Conclusions: The use of prophylactic PBM showed interesting clinical results. The decreased risk of weight loss and the protective effect on the development of severe OM may directly affect the quality of life of the patient, as well as allow for a higher rate of treatment compliance, fewer hospitalizations, and consequently reduce overall treatment costs.

show abstract

Section: Discussioncontrasting

confidence: 75%

Use of Photobiomodulation in Patients With Head and Neck Cancer Treated in an Oncology Service

Moura

Cruz

Santos

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…More studies about salivary microbiota are required. According to Amanda et al [ 22 ], photobiomodulation for oral mucositis has beneficial effects on preventing weight loss and reducing body mass index in HNC patients who received chemoradiotherapy. Generally, relieving oral mucositis can improve weight loss and nutritional condition.…”

Section: Discussionmentioning

confidence: 99%

The relationship of serum gastrin-17 and oral mucositis in head and neck carcinoma patients receiving radiotherapy

Liu

Shi

et al. 2022

Discov Onc

View full text Add to dashboard Cite

Objective The aim of this study was to analyze the relationship of serum gastrin-17 (G-17) and oral mucositis in head and neck carcinoma (HNC) patients receiving radiotherapy. Methods Serum G-17 were detected in patients before and after radiotherapy. Patients were divided into high G-17 group (baseline serum G-17 ≥ 5pmol/L) and low G-17 group (baseline serum G-17 < 5pmol/L). The severity of oral mucositis was analyzed between the two groups. Other complications such as dysphagia, salivary gland, mandible, thyroid function, larynx, pain, and weight loss were also investigated. Results Forty-two patients were analyzed in this study. The level of serum G-17 had a significant decrease after radiotherapy (7.29 ± 5.70pmol/L versus 4.93 ± 4.46pmol/L, P = 0.038). In low serum G-17 group, the incidences of grade 0, 1–2 and 3–4 of oral mucositis were 0%, 30.4%, and 69.6%, respectively. In high serum G-17 group, the incidences of grade 0, 1–2 and 3–4 of oral mucositis were 0%, 63.2%, and 36.8%, respectively. Pearson correlation analysis showed that serum G-17 was negatively correlated with oral mucositis (r=-0.595, P < 0.01). Weight loss of low G-17 group was more serious than that of high G-17 group. Conclusion Serum G-17 has a close relationship with oral mucositis. Baseline serum G-17 may be a potential predictor for the severity of oral mucositis in HNC patients receiving radiotherapy.

show abstract

“…Although the authors recommended glutamine to mitigate oral mucositis, there is also a need for highquality studies with a consensus of the methodology to reduce heterogeneity. According to Amanda et al [20], photobiomodulation for oral mucositis also shown positive impact to reduce weight loss and prevented a reduction in BMI in HNC patients who underwent chemoradiotherapy. Relieving oral mucositis can improve weight loss and nutritional status.…”

Section: Discussionmentioning

confidence: 99%

The Relationship of Serum Gastrin-17 and Oral Mucositis in Head and Neck Carcinoma Patients Receiving Radiotherapy

Liu

Shi

et al. 2022

Preprint

View full text Add to dashboard Cite

Objective The aim of this study was to analyze the relationship of serum gastrin-17 (G-17) and oral mucositis in head and neck carcinoma (HNC) patients receiving radiotherapy. Methods Serum G-17 were detected in patients before and after radiotherapy. Patients were divided into high G-17 group (baseline serum G-17 ≥ 5pmol/L) and low G-17 group (baseline serum G-17 < 5pmol/L). The severity of oral mucositis was analyzed between the two group. Other complications such as dysphagia, salivary gland, mandible, thyroid function, larynx, pain, and weight loss were also investigated. Results Forty-two patients were analyzed in this study. The median level of serum G-17 had a significant decrease after radiotherapy (7.29 ± 5.70pmol/L versus 4.93 ± 4.46pmol/L, P = 0.038). In low serum G-17 group, the incidences of grade 0, 1–2 and 3–4 of oral mucositis were 0%, 30.4%, and 69.6%, respectively. In high serum G-17 group, the incidences of grade 0, 1–2 and 3–4 of oral mucositis were 0%, 63.2%, and 36.8%, respectively. Pearson correlation analysis showed that serum G-17 was negatively correlated with oral mucositis (r=-0.595, P < 0.01). Weight loss of low G-17 group was more serious than that of high G-17 group. Conclusions Serum G-17 has a close relationship with oral mucositis. Baseline serum G-17 may be a potential predictor for the severity of oral mucositis in HNC patients receiving radiotherapy.

show abstract

Impact of photobiomodulation for oral mucositis on body weight and BMI of patients with head and neck cancer

Cited by 7 publications

References 27 publications

Use of Photobiomodulation in Patients With Head and Neck Cancer Treated in an Oncology Service

Use of Photobiomodulation in Patients With Head and Neck Cancer Treated in an Oncology Service

The relationship of serum gastrin-17 and oral mucositis in head and neck carcinoma patients receiving radiotherapy

The Relationship of Serum Gastrin-17 and Oral Mucositis in Head and Neck Carcinoma Patients Receiving Radiotherapy

Contact Info

Product

Resources

About